Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DAUNORUBICIN Cause Malignant neoplasm progression? 57 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 57 reports of Malignant neoplasm progression have been filed in association with DAUNORUBICIN (Daunorubicin Hydrochloride). This represents 0.6% of all adverse event reports for DAUNORUBICIN.

57
Reports of Malignant neoplasm progression with DAUNORUBICIN
0.6%
of all DAUNORUBICIN reports
17
Deaths
7
Hospitalizations

How Dangerous Is Malignant neoplasm progression From DAUNORUBICIN?

Of the 57 reports, 17 (29.8%) resulted in death, 7 (12.3%) required hospitalization, and 2 (3.5%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DAUNORUBICIN. However, 57 reports have been filed with the FAERS database.

What Other Side Effects Does DAUNORUBICIN Cause?

Febrile neutropenia (1,311) Pyrexia (645) Neutropenia (631) Sepsis (515) Off label use (462) Pneumonia (402) Bacterial infection (400) Drug ineffective (375) Septic shock (363) Thrombocytopenia (347)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which DAUNORUBICIN Alternatives Have Lower Malignant neoplasm progression Risk?

DAUNORUBICIN vs DAXIBOTULINUMTOXIN A-LANM DAUNORUBICIN vs DAYTRANA DAUNORUBICIN vs DECITABINE DAUNORUBICIN vs DEFERASIROX DAUNORUBICIN vs DEFERIPRONE

Related Pages

DAUNORUBICIN Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression DAUNORUBICIN Demographics